A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants
Latest Information Update: 06 Oct 2025
At a glance
- Drugs Pneumococcal 20-valent conjugate vaccine (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 08 Sep 2025 Planned End Date changed from 27 May 2027 to 1 May 2027.
- 08 Sep 2025 Planned primary completion date changed from 27 May 2027 to 1 May 2027.
- 08 Sep 2025 Status changed from recruiting to active, no longer recruiting.